Clinical Trial Update: Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 [Phase 3]

View source ↗

Summary

Phase 3 extension study update for SoluMatrix Abiraterone Acetate in patients who completed the primary study for prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• SoluMatrix Abiraterone Acetate (abiraterone acetate)

Snippet

Sponsor: GU Research Network, LLC | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED